Emerging strategies for EphA2 receptor targeting for cancer therapeutics

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 1, 2011, Pages 31-51

  Tandon, Manish ^a   Vemula, Sai Vikram ^a   Mittal, Suresh K ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Cancer; Cell signaling; Drug targets; EphA2; EphA2 overexpression; Ephrin; Receptor tyrosine kinase

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BI D1870; CARBOPLATIN; DASATINIB; DOCETAXEL; EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A2; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; MALEIMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EA5; NSC 35682; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SL 0101; STAUROSPORINE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER; BLADDER CANCER; BONE MARROW; BRAIN; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON; COLON CANCER; CYTOTOXICITY; DENDRITIC CELL; DEPHOSPHORYLATION; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; ENZYME INHIBITION; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY; KIDNEY CANCER; LIVER; LUNG; LUNG CANCER; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEAR INFRARED SPECTROSCOPY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OVARY TUMOR; PANCREAS CANCER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN; SMALL INTESTINE; SPLEEN; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TESTIS; THYMUS; TRANSGENIC MOUSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UTERUS; VULVA CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; RECEPTOR, EPHA2; SIGNAL TRANSDUCTION;

EID: 78650193841     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.538682     Document Type: Review

References (157)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
2. Hunter T, Lindberg RA, Middlemas DS, et al. Receptor protein tyrosine kinases and phosphatases. Cold Spring Harb Symp Quant Biol 1992;57:25-41
3. Hunter T. Signaling - 2000 and beyond. Cell 2000;100:113-27
4. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:F217-48
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-70 (Pubitemid 38579482)
6. Gale NW, Yancopoulos GD. Ephrins and their receptors: A repulsive topic? Cell Tissue Res 1997;290:227-41
7. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3:475-86
8. Murai KK, Pasquale EB. 'Eph'ective signaling: Forward, reverse and crosstalk. J Cell Sci 2003;116:2823-32
9. Hirai H, Maru Y, Hagiwara K, et al. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987;238:1717-20 . The cloning of the EphA1 gene is described.
10. Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 1990;10:6316-24 . The identification of EphA2 and its expression primarily in epithelial cells is described.
11. Ruiz JC, Robertson EJ. The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 1994;46:87-100
12. Himanen JP, Goldgur Y, Miao H, et al. Ligand recognition by A-class Eph receptors: Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep 2009;10:722-8 . This paper describes the determination of the crystal structures of EphA2 and ephrinA1 as the interaction of a 'lock and key' mechanism.
13. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997;9:608-15
14. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6:462-75
15. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol Cancer Res 2008;6:1795-806
16. Binns KL, Taylor PP, Sicheri F, et al. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol 2000;20:4791-805
17. Holzman LB, Marks RM, Dixit VM. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 1990;10:5830-8 . The identification of ephrinA1 is described.
18. Bartley TD, Hunt RW, Welcher AA, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994;368:558-60 . The identification of ephrinA1 as a ligand for EphA2 is described.
19. Seiradake E, Harlos K, Sutton G, et al. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 2010;17:398-402 . This paper describes the determination of the crystal structures of the extracellular domain of EphA2 in complex with ligand binding domain of ephrinA5.
20. Himanen JP, Yermekbayeva L, Janes PW, et al. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA 2010;107:10860-5 . An analysis of the crystal structures of the extracellular domain of EphA2 in a complex with ephrinA5 and ephrinA1.
21. Shao H, Pandey A, O'Shea KS, et al. Characterization of B61, the ligand for the Eck receptor protein-tyrosine kinase. J Biol Chem 1995;270:5636-41
22. Shao H, Lou L, Pandey A, et al. cDNA cloning and characterization of a Cek7 receptor protein-tyrosine kinase ligand that is identical to the ligand (ELF-1) for the Mek-4 and Sek receptor protein-tyrosine kinases. J Biol Chem 1995;270:3467-70
23. Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 2004;7:417-8
24. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52
25. Salaita K, Nair PM, Petit RS, et al. Restriction of receptor movement alters cellular response: Physical force sensing by EphA2. Science 2010;327:1380-5
26. Zisch AH, Pasquale EB. The Eph family: A multitude of receptors that mediate cell recognition signals. Cell Tissue Res 1997;290:217-26
27. Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006;312:642-50
28. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85
29. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33
30. Vaught D, Brantley-Sieders DM, Chen J. Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression. Breast Cancer Res 2008;10:217
31. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003;20:59-68
32. Hafner C, Becker B, Landthaler M, Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 2006;19:1369-77
33. Andres AC, Zuercher G, Djonov V, et al. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int J Cancer 1995;63:288-96
34. Andres AC, Ziemiecki A. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J Mammary Gland Biol Neoplasia 2003;8:475-85
35. Zelinski DP, Zantek ND, Stewart JC, et al. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-6 . The identification of a differential expression pattern of EphA2 in normal and cancer cells and the linkage to EphA2 overexpression in normal cells to oncogenic transformation is described.
36. Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001;7:3640-8
37. Zelinski DP, Zantek ND, Walker-Daniels J, et al. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J Cell Biochem 2002;85:714-20
38. Lu M, Miller KD, Gokmen-Polar Y, et al. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 2003;63:3425-9
39. Zhuang G, Brantley-Sieders DM, Vaught D, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010;70:299-308 . A report demonstrating that EphA2 overexpression contributes to the development of resistance towards Her2 antibody treatment.
40. Easty DJ, Guthrie BA, Maung K, et al. Protein B61 as a new growth factor: Expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995;55:2528-32
41. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494-501
42. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene 2003;22:3070-5
43. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61:3250-5 A report demonstrating that EphA2 expression and phosphorylation is functionally important in aggressive melanoma cells.
44. Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: Implications for vasculogenic mimicry. Cancer Biol Ther 2006;5:228-33 . A report of EphA2 regulation by VE-cadherin in melanoma.
45. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002;160:1009-19
46. Margaryan NV, Strizzi L, Abbott DE, et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009;8:279-88
47. Parri M, Taddei ML, Bianchini F, et al. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 2009;69:2072-81 . A report showing that EphA2 expression could determine cancer cell migration pattern.
48. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145-50
49. Han L, Dong Z, Qiao Y, et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 2005;99:278-86 The determination of EphA2 expression levels in ovarian cancers and an exploration of its prognostic value.
50. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005;9:1179-87
51. Lu C, Shahzad MM, Wang H, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008;7:1098-103 A report of a relationship between EphA2, cell adhesion and angiogenesis in ovarian cancers.
52. Merritt WM, Thaker PH, Landen CN Jr, et al. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther 2006;5:1357-60
53. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007;109:332-40 . The determination that EphA2 overexpression correlates to markers of angiogenesis is described.
54. Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613-18 The identification of EphA2 as a potential lung cancer biomarker with prognostic value is described.
55. Brannan JM, Dong W, Prudkin L, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009;15:4423-30
56. Faoro L, Singleton PA, Cervantes GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 2010;285:18575-85 . The identification of a mutation of EphA2 in lung squamous cell carcinoma and the determination of its functional relevance in lung cancer cell lines is descibed.
57. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004;4:218-27
58. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005;3:541-51 The identification of EphA2 overexpression as a putative marker for glioblastoma.
59. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: A novel target for glioma vaccines. Neoplasia 2005;7:717-22 A report demonstrating that EphA2-derived peptides could function in glioma vaccines.
60. Li X, Wang Y, Wang Y, et al. Expression of EphA2 in human astrocytic tumors: Correlation with pathologic grade, proliferation and apoptosis. Tumour Biol 2007;28:165-72
61. Liu F, Park PJ, Lai W, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 2006;66:10815-23
62. Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 2008;19:151-6 A report demonstrating that increased EphA2 expression is associated with poor outcomes in glioblastoma patients. (Pubitemid 351176143)
63. Abraham S, Knapp DW, Cheng L, et al. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006;12:353-60 An investigation of EphA2 expression in urinary bladder carcinoma and the determination of its significance as a target for bladder cancer therapy.
64. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-80 A report on the EphA2 expression pattern in prostate cancer cell lines and clinical specimens.
65. Miyazaki T, Kato H, Fukuchi M, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003;103:657-63 An investigation of EphA2 expression in clinical esophageal squamous cell carcinoma and the determination of its prognostic importance.
66. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003;63:4481-9 . A report on EphA2-derived peptides as targets of adaptive immune response and their potential to predict disease progression.
67. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005;11:226-31
68. Rosenberg IM, Goke M, Kanai M, et al. Epithelial cell kinase-B61: An autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997;273:G824-32
69. Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004;95:136-41
70. Li Z, Tanaka M, Kataoka H, et al. EphA2 up-regulation induced by deoxycholic acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independence. J Cancer Res Clin Oncol 2003;129:703-8
71. Holm R, Knopp S, Suo Z, et al. Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. J Clin Pathol 2007;60:1086-91 An investigation of EphA2 and ephrinA1 expression in vulvar squamous cell carcinoma with respect to the prognostic relevance.
72. Taddei ML, Parri M, Angelucci A, et al. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 2009;174:1492-503
73. Zantek ND, Azimi M, Fedor-Chaiken M, et al. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999;10:629-38
74. Guo H, Miao H, Gerber L, et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006;66:7050-8 . A report on a tumor suppressor role of EphA2 in a mice model of skin carcinogenesis.
75. Himanen JP, Rajashankar KR, Lackmann M, et al. Crystal structure of an Eph receptor-ephrin complex. Nature 2001;414:933-8 . A report on the crystal structure of EphB2 ad ephrinB2 complex.
76. Wykosky J, Palma E, Gibo DM, et al. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008;27:7260-73
77. Noren NK, Pasquale EB. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal 2004;16:655-66
78. Pandey A, Lazar DF, Saltiel AR, Dixit VM. Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem 1994;269:30154-7
79. Pandey A, Duan H, Dixit VM. Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J Biol Chem 1995;270:19201-4
80. Miao H, Burnett E, Kinch M, et al. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000;2:62-9 An investigation of the mechanisms of EphA2 signaling in cell adhesion and migration.
81. Carter N, Nakamoto T, Hirai H, Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130cas. Nat Cell Biol 2002;4:565-73 An investigation of the mechanism of EphA2-ephrinA1 signaling in cell adhesion and cytoskeleton organization.
82. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002;21:7690-9 The determination of the linking of EphA2 signaling to MAPK signaling pathway is described.
83. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001;3:527-30 The identification of EphA2-ephrinA1 signaling as a negative regulator of MAPK signaling.
84. Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005;8:111-18 A report on EphA2 as a target of the MAPK signaling pathway.
85. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 2008;27:2934-40
86. Brantley-Sieders DM, Chen J. Eph receptor tyrosine kinases in angiogenesis: From development to disease. Angiogenesis 2004;7:17-28 (Pubitemid 39127767)
87. Brantley-Sieders DM, Fang WB, Hicks DJ, et al. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005;19:1884-6
88. Hunter SG, Zhuang G, Brantley-Sieders D, et al. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol 2006;26:4830-42
89. Brantley-Sieders DM, Fang WB, Hwang Y, et al. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 2006;66:10315-24
90. Huber O, Bierkamp C, Kemler R. Cadherins and catenins in development. Curr Opin Cell Biol 1996;8:685-91
91. Orsulic S, Kemler R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000;113(Pt 10):1793-802 A report demonstrating that EphA2 is regulated by E-cadherin in embryonic stem cells.
92. Larsen AB, Stockhausen MT, Poulsen HS. Cell adhesion and EGFR activation regulate EphA2 expression in cancer. Cell Signal 2010;22:636-44
93. Dohn M, Jiang J, Chen X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 2001;20:6503-15 The identification of p53 response elements in the EphA2 promotor and the regulation of EphA2 by p53 is descibed.
94. Zhang G, Njauw CN, Park JM, et al. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008;68:1691-6
95. Pratt RL, Kinch MS. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol Cancer Res 2003;1:1070-6 A report on a mechanism of EphA2 gene expression regulation by its ligand ephrinA1.
96. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7 . The development of monoclonal antibodies against EphA2 that suppress malignant behavior of breast cancer-derived cells is described.
97. Walker-Daniels J, Riese DJ, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002;1:79-87
98. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003;162:1037-42
99. Zhuang G, Hunter S, Hwang Y, Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation. J Biol Chem 2007;282:2683-94
100. Kawabe M, Mandic M, Taylor JL, et al. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17- demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res 2009;69:6995-7003
101. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9
102. Landen CN Jr, Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98:1558-70
103. Hammond SA, Lutterbuese R, Roff S, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res 2007;67:3927-35 . The development of a bispecific antibody targeting EphA2 on tumor cells and a T-cell receptor on T cells in order to direct a cytotoxic response against tumors is described.
104. Coffman KT, Hu M, Carles-Kinch K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 2003;63:7907-12
105. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-7
106. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009;101:1193-205 . A report on the anti-tumor activity of the EphA2 monoclonal antibody linked to a chemotherapeutic agent in preclinical ovarian cancer models.
107. Lee JW, Stone RL, Lee SJ, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 2010;16:2562-70
108. Cai W, Ebrahimnejad A, Chen K, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007;34:2024-36
109. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 2007;6:3208-18 . The development of ephrinA1-PE38QQR (ephrinA1 conjugated to a toxin) to target EphA2-overexpressing cancers is described.
110. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7
111. Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leuk Res 2004;28(Suppl 1):S29-38
112. Noberini R, Koolpe M, Peddibhotla S, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008;283:29461-72 . The identification of small-molecule inhibitors of EphA4 and EphA2 by high-throughput screening is described.
113. Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 2008;99:1074-82 . A report demonstrating that a Src family inhibitor Dasatinib inhibits EphA2 in pancreatic cancer models.
114. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41 (Pubitemid 43882349)
115. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32
116. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9
117. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
118. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection. Cancer Res 2007;67:2226-38 (Pubitemid 46424242)
119. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44
120. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63
121. Wang XD, Reeves K, Luo FR, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255
122. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006;2:137-43
123. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25:462-6
124. Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 2008;4:117-38
125. Noblitt LW, Bangari DS, Shukla S, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004;11:757-66 . The development of adenoviral vectors expressing a secretory form of ephrinA1 to target EphA2 overexpression is described.
126. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995;92:8522-6
127. Noblitt LW, Bangari DS, Shukla S, et al. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 2005;12:46-53 . A report on the stimulation of intratumoral breast cancer targeted via adenoviral vectors in a mouse model of mammary tumorigenesis.
128. Brantley-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008;118:64-78
129. Van Geer MA, Brevoord D, Kuhlmann KF, et al. A fiber modified adenovirus vector that targets to the EphrinA2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer. Int J Oncol 2010;36:233-44
130. Honeyman MC, Brusic V, Stone NL, Harrison LC. Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol 1998;16:966-9
131. Alves PM, Faure O, Graff-Dubois S, et al. EphA2 as target of anticancer immunotherapy: Identification of HLA.-A.*0201-restricted epitopes. Cancer Res 2003;63:8476-80 A proposal of EphA2 as a tumor-associated antigen and identification of functional EphA2-derived peptides for immunotherapy.
132. Yamaguchi S, Tatsumi T, Takehara T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007;110:1469-77 . An investigation of EphA2 expression in colon cancer specimens and the development of a dendritic cell pulsed with EphA2-derived peptides as a strategy for vaccination in a mouse model of colon cancer.
133. Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002;277:39274-9
134. Duxbury MS, Ito H, Zinner MJ, et al. EphA2: A determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004;23:1448-56
135. Prasad NK, Tandon M, Badve S, et al. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008;29:25-34
136. Prasad NK, Tandon M, Handa A, et al. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol 2008;29:330-41
137. Zhou Z, Yuan X, Li Z, et al. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol 2008;70:562-8
138. Larsen AB, Pedersen MW, Stockhausen MT, et al. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007;5:283-93 A report on a functional crosstalk between EphA2 and EGFR signaling.
139. Pedersen MW, Pedersen N, Damstrup L, et al. Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J Cell Biochem 2005;96:412-27
140. Nasreen N, Mohammed KA, Antony VB. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006;107:2425-35
141. Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009;8:1027-34 A report demonstrating that dual EphA2 and FAK silencing shows enhanced effects in ovarian cancer models compared to monotherapy.
142. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24
143. Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm Res 2006;23:1417-50
144. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100:13549-54
145. O'Neal DP, Hirsch LR, Halas NJ, et al. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 2004;209:171-6
146. Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005;1:325-7
147. Gobin AM, Moon JJ, West JL. EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomedicine 2008;3:351-8 . A report on the application of gold-coated silica nanoshells conjugated to ephrinA1 to target EphA2 overexpressing prostate cancer-derived cells.
148. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc 2008;130:10258-62 . A report on the testing of EphA2-targeting magnetic nanoparticles in ovarian cancer cells.
149. Dickerson EB, Blackburn WH, Smith MH, et al. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010;10:10 . A report on the targeting of EGFR by using siRNA delivery via nanoparticles conjugated to an EphA2-mimetic peptide.
150. Yamaguchi S, Tatsumi T, Takehara T, et al. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother 2008;57:1861-9
151. Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-18 The investigation of EphA2 siRNA encapsulated in liposomes for delivery in a mouse model of ovarian cancer.
152. Wesa AK, Herrem CJ, Mandic M, et al. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J Immunol 2008;181:7721-7
153. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300
154. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008;14:199-208
155. Zeng G, Hu Z, Kinch MS, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-6
156. Yuan W, Chen Z, Wu S, et al. Expression of EphA2 and E-cadherin in gastric cancer: Correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 2009;15:473-8
157. Yuan WJ, Ge J, Chen ZK, et al. Over-expression of EphA2 and ephrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2009;54:2410-17